Similarly, statistical significance was not achieved for PFS or ORR (Figure 4 A,B; Table 2 ); however, there was a nonsignificant trend toward improved PFS in the ruxolitinib group compared with the placebo group in substudy 2 (Figure 4 B).
← all excerpts
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
1
—
—